3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
52
Breast Neoplasms
24
Lung Neoplasms
21
Triple Negative Breast Neoplasms
16
Neoplasm Metastasis
16
Pancreatic Neoplasms
15
Neoplasms
15
Colorectal Neoplasms
14
Stomach Neoplasms
13
Head and Neck Neoplasms
12
Esophageal Neoplasms
12
Esophageal Squamous Cell Carcinoma
11
Uterine Cervical Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
10
Small Cell Lung Carcinoma
9
Rectal Neoplasms
8
Ovarian Neoplasms
8
Leukemia, Myeloid, Acute
8
Recurrence
7
Nasopharyngeal Carcinoma
7
Glioblastoma
5
Fallopian Tube Neoplasms
5
Cholangiocarcinoma
5
Urinary Bladder Neoplasms
4
Sarcoma
4
Oropharyngeal Neoplasms
4
Mouth Neoplasms
4
Lymphoma
4
Endometrial Neoplasms
4
Colonic Neoplasms
4
Interventions
Nivolumab
6
atezolizumab
5
Cisplatin
5
Ipilimumab
4
Carboplatin
4
Etoposide
3
pembrolizumab
2
gallium Ga 68 dotatate
2
dostarlimab
2
Temozolomide
2
Positron Emission Tomography Computed Tomography
2
Paclitaxel
2
Magnetic Resonance Imaging
2
Irinotecan
2
Immunoglobulin G
2
IFL protocol
2
Disulfides
2
zimberelimab
1
tivozanib
1
repotrectinib
1
niraparib
1
lutetium Lu 177 dotatate
1
lenvatinib
1
iadademstat
1
durvalumab
1
cabozantinib
1
budigalimab
1
belinostat
1
Topotecan
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Neuroendocrine
×
Drug Therapy
×
1 year
×
Clear all
NCT06333314
2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2
Recruiting
120 enrolled